Phase 3 Comparative Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis (SYMPHONY ND)

Phase 3 Study to Compare the Efficacy and Safety of JTZ-951 with Darbepoetin Alfa in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis (SYMPHONY ND)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223814

Enrollment

200

Registered

2018-02-19

Start date

2018-02-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia with CKD

Interventions

investigational material(s) Generic name etc : JTZ-951 INN of investigational material : Enarodustat Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Administ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ESA naive patients: Hemoglobin level of => 8.0 g/dL and = 9.5 g/dL and =< 12.0 g/dL

Exclusion criteria

Exclusion criteria: Patients with poorly controlled hypertension Patients with congestive heart failure or unstable angina Patients with malignancy

Design outcomes

Primary

Measure	Time frame
efficacy Difference in mean Hb level between arms during the evaluation period	—

Secondary

Measure	Time frame
efficacy Observed Hb level at each Visit Change in Hb level at each Visit	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026